Most efforts aimed at understanding the notable heterogeneity of outcomes in multiple sclerosis (MS) have focused on disease-specific factors, such as symptoms at initial presentation, initial relapse rate, and age at symptom onset. These factors, however, explain relatively little of the heterogeneity of disease outcomes. Owing to the high prevalence of comorbidity in MS and the potential for its prevention or treatment, comorbidity is of rising interest as a factor that could explain the heterogeneity of outcomes. A rapidly growing body of evidence suggests that comorbidity adversely affects outcomes throughout the disease course in MS, including diagnostic delays from symptom onset, disability at diagnosis and subsequent progression, cognition, mortality, and health-related quality of life. Therefore, clinicians need to incorporate the prevention and management of comorbidity when treating patients with MS, but managing comorbidities in MS successfully may require the adoption of new collaborative models of care.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Langer-Gould, A. et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch. Neurol. 63, 1686–1691 (2006).
Wingerchuk, D. M. & Weinshenker, B. G. Disease modifying therapies for relapsing multiple sclerosis. BMJ 354, i3518 (2016).
McKay, K. A., Jahanfar, S., Duggan, T., Tkachuk, S. & Tremlett, H. Factors associated with onset, relapses or progression in multiple sclerosis: a systematic review. Neurotoxicology http://dx.doi.org/10.1016/j.neuro.2016.03.020 (2016).
Gijsen, R. et al. Causes and consequences of comorbidity: a review. J. Clin. Epidemiol. 54, 661–674 (2001).
Feinstein, A. et al. Diffusion tensor imaging abnormalities in depressed multiple sclerosis patients. Mult. Scler. 16, 189–196 (2010).
Patten, S. B., Metz, L. M. & Reimer, M. A. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult. Scler. 6, 115–120 (2000).
Marrie, R. A. et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult. Scler. 21, 263–281 (2015).
Langer-Gould, A., Albers, K., Van Den Eeden, S. & Nelson, L. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult. Scler. 16, 855–861 (2010).
Marrie, R. A., Horwitz, R. I., Cutter, G., Tyry, T. & Vollmer, T. Association between comorbidity and clinical characteristics of MS. Acta Neurol. Scand. 124, 135–141 (2011).
Marrie, R. A. et al. Sex differences in comorbidity at diagnosis of multiple sclerosis: a population-based study. Neurology 86, 1279–1286 (2016).
Hoang, H., Laursen, B., Stenager, E. N. & Stenager, E. Psychiatric co-morbidity in multiple sclerosis: the risk of depression and anxiety before and after MS diagnosis. Mult. Scler. 22, 347–353 (2016).
Marrie, R. A. et al. Rising prevalence of vascular comorbidities in MS: validation of administrative definitions for diabetes, hypertension, hyperlipidemia. Mult. Scler. 18, 1310–1319 (2012).
Marrie, R. A. et al. Differing trends in the incidence of vascular comorbidity in MS and the general population. Neurol. Clin. Pract. 6, 120–128 (2016).
Marrie, R. A. et al. The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: a population-based study. Mult. Scler. Relat. Disord. 1, 162–167 (2012).
Marrie, R. A. et al. The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiology 40, 85–92 (2013).
Marrie, R. A. et al. Differences in the burden of psychiatric comorbidity in MS versus the general population. Neurology 85, 1972–1979 (2015).
Berrigan, L. I. et al. Health-related quality of life in multiple sclerosis: direct and indirect effects of comorbidity. Neurology 86, 1417–1424 (2016).
Browne, R. W. et al. Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. J. Neurol. Neurosurg. Psychiatry 85, 859–864 (2014).
Chruzander, C. et al. A 10-year follow-up of a population-based study of people with multiple sclerosis in Stockholm, Sweden: changes in disability and the value of different factors in predicting disability and mortality. J. Neurol. Sci. 332, 121–127 (2013).
Finlayson, M., Preissner, K. & Cho, C. Impact of comorbidity on fatigue management intervention outcomes among people with multiple sclerosis. Int. J. MS Care 15, 21–26 (2013).
Marrie, R. A. et al. Effect of comorbidity on mortality in multiple sclerosis. Neurology 85, 240–247 (2015).
Marrie, R. A. et al. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 72, 117–124 (2009).
Marrie, R. A. et al. Comorbidity increases the risk of hospitalizations in multiple sclerosis. Neurology 84, 350–358 (2015).
Marck, C. H., Neate, S. L., Taylor, K. L., Weiland, T. J. & Jelinek, G. A. Prevalence of comorbidities, overweight and obesity in an international sample of people with multiple sclerosis and associations with modifiable lifestyle factors. PLoS ONE 11, e0148573 (2016).
Espinola-Nadurille, M. et al. Mental disorders in Mexican patients with multiple sclerosis. J. Neuropsychiatry Clin. Neurosci. 22, 63–69 (2010).
Tettey, P. et al. Adverse lipid profile is not associated with relapse risk in MS: results from an observational cohort study. J. Neurol. Sci. 340, 230–232 (2014).
Gee, J. R., Chang, J., Dublin, A. B. & Vijayan, N. The association of brainstem lesions with migraine-like headache: an imaging study of multiple sclerosis. Headache 45, 670–677 (2005).
Tortorella, P. et al. Assessment of MRI abnormalities of the brainstem from patients with migraine and multiple sclerosis. J. Neurol. Sci. 244, 137–141 (2006).
Graziano, E., Hagemeier, J., Weinstock-Guttman, B., Ramasamy, D. P. & Zivadinov, R. Increased contrast enhancing lesion activity in relapsing-remitting multiple sclerosis migraine patients. Neuroimage Clin. 9, 110–116 (2015).
Weinstock-Guttman, B. et al. Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. J. Neurol. Neurosurg. Psychiatry 84, 1186–1191 (2013).
Weinstock-Guttman, B. et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J. Neuroinflamm. 8, 127 (2011).
Giubilei, F. et al. Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. Acta Neurol. Scand. 106, 109–112 (2002).
Rao, S. M., Leo, G. J., Bernardin, L. & Unverzagt, F. Cognitive dysfunction in multiple sclerosis I: frequency, patterns, and predictions. Neurology 41, 685–691 (1991).
Rocca, M. A. et al. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol. 14, 302–317 (2015).
Moller, A., Wiedemann, G., Rohde, U., Backmund, H. & Sonntag, A. Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatr. Scand. 89, 117–121 (1994).
DeLuca, J., Barbieri-Berger, S. & Johnson, S. K. The nature of memory impairments in multiple sclerosis: acquisition versus retrieval. J. Clin. Exp. Neuropsychol. 16, 183–189 (1994).
Arnett, P. A., Higginson, C. I. & Randolph, J. J. Depression in multiple sclerosis: relationship to planning ability. J. Int. Neuropsychol. Soc. 7, 665–674 (2001).
Arnett, P. A. et al. Depression in multiple sclerosis: relationship to working memory capacity. Neuropsychology 13, 546–556 (1999).
Niino, M. et al. Apathy/depression, but not subjective fatigue, is related with cognitive dysfunction in patients with multiple sclerosis. BMC Neurol. 14, 3 (2014).
Goretti, B. et al. Anxiety state affects information processing speed in patients with multiple sclerosis. Neurol. Sci. 35, 559–563 (2014).
Morrow, S. A., Rosehart, H. & Pantazopoulos, K. Anxiety and depressive symptoms are associated with worse performance on objective cognitive tests in MS. J. Neuropsychiatry Clin. Neurosci. 28, 118–123 (2015).
Millan, M. J. et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat. Rev. Drug Discov. 11, 141–168 (2012).
Oliveira, S. R. et al. Disability in patients with multiple sclerosis: influence of insulin resistance, adiposity, and oxidative stress. Nutrition 30, 268–273 (2014).
Moccia, M. et al. The Framingham cardiovascular risk score in multiple sclerosis. Eur. J. Neurol. 22, 1176–1183 (2015).
Marrie, R. A. et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 74, 1041–1047 (2010).
Tettey, P. et al. An adverse lipid profile is associated with disability and progression in disability, in people with MS. Mult. Scler. 20, 1737–1744 (2014).
Dallmeijer, A. J. et al. Long-term effect of comorbidity on the course of physical functioning in patients after stroke and with multiple sclerosis. J. Rehabil. Med. 41, 322–326 (2009).
Tinghog, P. et al. Co-morbidities increase the risk of disability pension among MS patients: a population-based nationwide cohort study. BMC Neurol. 14, 117 (2014).
Mitchell, A. J., Benito-León, J., González, J.-M. M. & Rivera-Navarro, J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol. 4, 556–566 (2005).
Turpin, K. V., Carroll, L. J., Cassidy, J. D. & Hader, W. J. Deterioration in the health-related quality of life of persons with multiple sclerosis: the possible warning signs. Mult. Scler. 13, 1038–1045 (2007).
Warren, S. A., Turpin, K. V., Pohar, S. L., Jones, C. A. & Warren, K. G. Comorbidity and health-related quality of life in people with multiple sclerosis. Int. J. MS Care 11, 6–16 (2009).
Kingwell, E. et al. Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. J. Neurol. Neurosurg. Psychiatry 83, 61–66 (2012).
Ragonese, P. et al. Multiple sclerosis survival: a population-based study in Sicily. Eur. J. Neurol. 17, 391–397 (2010).
Hirst, C., Swingler, R., Compston, D. A. S., Ben-Shlomo, Y. & Robertson, N. P. Survival and cause of death in multiple sclerosis: a prospective population-based study. J. Neurol. Neurosurg. Psychiatry 79, 1016–1021 (2008).
Krokki, O., Bloigu, R., Ansakorpi, H., Reunanen, M. & Remes, A. M. Neurological comorbidity and survival in multiple sclerosis. Mult. Scler. Relat. Disord. 3, 72–77 (2013).
Turner, A. P., Hartoonian, N., Maynard, C., Leipertz, S. L. & Haselkorn, J. K. Smoking and physical activity: examining health behaviors and 15-year mortality among individuals with multiple sclerosis. Arch. Phys. Med. Rehabil. 96, 402–409 (2015).
Marrie, R. A. et al. The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology 86, 1437–1445 (2016).
Zhang, T. et al. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology 86, 1287–1295 (2016).
Turner, B. J., Hollenbeak, C. S., Weiner, M., Ten Have, T. & Tang, S. S. K. Effect of unrelated comorbid conditions on hypertension management. Ann. Intern. Med. 148, 578–586 (2008).
Redelmeier, D. A., Tan, S. H. & Booth, G. L. The treatment of unrelated disorders in patients with chronic medical diseases. N. Engl. J. Med. 338, 1516–1520 (1998).
Kalsekar, I. D. et al. Impact of depression on utilization patterns of oral hypoglycemic agents in patients newly diagnosed with type 2 diabetes mellitus: a retrospective cohort analysis. Clin. Ther. 28, 306–318 (2006).
The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 655–661 (1993).
Patten, S. B. & Metz, L. M. Interferon β1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology 59, 744–746 (2002).
Caraccio, N. et al. Long-term follow-up of 106 multiple sclerosis patients undergoing Interferon-β 1a or 1b therapy: predictive factors of thyroid disease development and duration. J. Clin. Endocrinol. Metab. 90, 4133–4137 (2005).
Polman, C. H. et al. Interferon beta-1b treatment does not induce autoantibodies. Neurology 64, 996–1000 (2005).
Chouhfeh, L., Kavak, K. S., Teter, B. E. & Weinstock-Guttman, B. Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients. Mult. Scler. Relat. Disord. 4, 228–233 (2015).
The CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786–1801 (2008).
Cohen, J. A. et al. Alemtuzumab versus Interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380, 1819–1828 (2012).
Cossburn, M. et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 77, 573–579 (2011).
Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387–401 (2010).
Sternberg, Z., Leung, C., Sternberg, D., Yu, J. & Hojnacki, D. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis. Cardiovasc. Ther. 32, 33–39 (2014).
Patti, F. et al. Frequency and severity of headache is worsened by Interferon-β therapy in patients with multiple sclerosis. Acta Neurol. Scand. 125, 91–95 (2012).
Villani, V. et al. The impact of interferon beta and natalizumab on comorbid migraine in multiple sclerosis. Headache 52, 1130–1135 (2012).
Jain, N. & Bhatti, M. T. Fingolimod-associated macular edema: incidence, detection, and management. Neurology 78, 672–680 (2012).
Tengland, P. A. Behavior change or empowerment: on the ethics of health-promotion goals. Health Care Anal. 24, 24–46 (2016).
Healy, B. C. et al. Smoking and disease progression in multiple sclerosis. Arch. Neurol. 66, 858–864 (2009).
Fiest, K. M. et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult. Scler. Relat. Disord. 5, 12–26 (2016).
Raissi, A. et al. Exploration of undertreatment and patterns of treatment of depression in multiple sclerosis. Int. J. MS Care 17, 292–300 (2015).
Patten, S. B. et al. Validity of four screening scales for major depression in MS. Mult. Scler. 21, 1064–1071 (2015).
Litster, B. et al. Screening tools for anxiety in persons with multiple sclerosis: a systematic review. Int. J. MS Care 18, 273–281 (2016).
Anderson, J. E., Michalak, E. E. & Lam, R. W. Depression in primary care: tools for screening, diagnosis, and measuring response to treatment. BC Med. J. 44, 415–419 (2002).
Gilbody, S., Sheldon, T. & House, A. Screening and case-finding instruments for depression: a meta-analysis. Can. Med. Assoc. J. 178, 997–1003 (2008).
Roy-Byrne, P. et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA 303, 1921–1928 (2010).
Gilbody, S., Bower, P., Fletcher, J., Richards, D. & Sutton, A. J. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch. Intern. Med. 166, 2314–2321 (2006).
Negrotto, L., Farez, M. F. & Correale, J. Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis. JAMA Neurol. 73, 520–528 (2016).
Siu, A. L. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 163, 861–868 (2015).
Khurana, S. R. et al. Prevalence of overweight and obesity among Veterans with multiple sclerosis. Am. J. Phys. Med. Rehabil. 88, 83–91 (2009).
US Preventive Services Task Force. Screening adults for lipid disorders: recommendations and rationale. Am. J. Prev. Med. 20, 73–76 (2001).
Raney, L. E. Integrating primary care and behavioral health: the role of the psychiatrist in the collaborative care model. Am. J. Psychiatry 172, 721–728 (2015).
Atlantis, E., Fahey, P. & Foster, J. Collaborative care for comorbid depression and diabetes: a systematic review and meta-analysis. BMJ Open 4, e004706 (2014).
Dougados, M. et al. Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). Ann. Rheum. Dis. 74, 1725–1733 (2015).
Hankin, B. L. Future directions in vulnerability to depression among youth: integrating risk factors and processes across multiple levels of analysis. J. Clin. Child Adolesc. Psychol. 41, 695–718 (2012).
Maddock, C. & Pariante, C. M. How does stress affect you? An overview of stress, immunity, depression and disease. Epidemiol. Psichiatr. Soc. 10, 153–162 (2001).
Patten, S. B. Major depression epidemiology from a diathesis-stress conceptualization. BMC Psychiatry 13, 19 (2013).
Mohr, D. C., Hart, S. L., Julian, L., Cox, D. & Pelletier, D. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 27, 731–735 (2004).
Burns, M. N., Nawacki, E., Kwasny, M. J., Pelletier, D. & Mohr, D. C. Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis? Psychol. Med. 44, 349–359 (2014).
Gulick, E. E. Emotional distress and activities of daily living functioning in persons with multiple sclerosis. Nurs. Res. 50, 147–154 (2001).
Irwin, M. R. & Miller, A. H. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav. Immun. 21, 374–383 (2007).
Dowlati, Y. et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67, 446–457 (2010).
Furtado, M. & Katzman, M. A. Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders. Psychiatry Res. 229, 37–48 (2015).
Vieira, M. M. M. et al. Enhanced Th17 phenotype in individuals with generalized anxiety disorder. J. Neuroimmunol. 229, 212–218 (2010).
Chataway, J. et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 383, 2213–2221 (2014).
Lanzillo, R. et al. No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). Mult. Scler. 22, 1163–1173 (2016).
Kavalipati, N., Shah, J., Ramakrishan, A. & Vasnawala, H. Pleiotropic effects of statins. Indian J. Endocrinol. Metab. 19, 554–562 (2015).
Kappus, N. et al. Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 87, 181–187 (2015).
Kister, I. et al. Migraine is comorbid with multiple sclerosis and associated with a more symptomatic MS course. J. Headache Pain 11, 417–425 (2010).
Uribe-San-Martin, R. et al. Prevalence of epilepsy in a cohort of patients with multiple sclerosis. Seizure 23, 81–83 (2014).
Zivadinov, R. et al. Autoimmune comorbidities are associated with brain injury in multiple sclerosis. AJNR Am. J. Neuroradiol. 37, 1010–1016 (2016).
British Columbia Ministry of Health. Integrated models of primary care and mental health & substance use care in the community. Health – Province of British Columbia http://www.health.gov.bc.ca/library/publications/year/2012/integrated-models-lit-review.pdf (2012).
This article was supported (in part) by a Don Paty Career Development award from the MS Society of Canada, a Manitoba Research Chair from Research Manitoba, and the Waugh Family Chair in Multiple Sclerosis. R.A.M. receives research funding from Canadian Institutes of Health Research, Research Manitoba, MS Society of Canada, MS Scientific Foundation, National MS Society, Rx & D Health Research Foundation.
R.A.M has conducted clinical trials for Sanofi-Aventis (funds awarded to institution with no personal compensation).
About this article
Cite this article
Marrie, R. Comorbidity in multiple sclerosis: implications for patient care. Nat Rev Neurol 13, 375–382 (2017). https://doi.org/10.1038/nrneurol.2017.33
Proposed minimal essential co-expression and physical interaction networks involved in the development of cognition impairment in human mid and late life
Neurological Sciences (2020)
Multiple Sclerosis and Related Disorders (2020)
Multiple Sclerosis and Related Disorders (2020)
Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England
JAMA Neurology (2020)
Comorbidities are prevalent and detrimental for employment outcomes in people of working age with multiple sclerosis
Multiple Sclerosis Journal (2020)